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862Maintaining Hematopoietic
Stem Cells in the Vascular Niche
In this issue of Immunity, Sugiyama et al. (2006)
provide evidence that most bone-marrow hematopoi-
etic stem cells (HSCs) reside in vascular niches
containing reticular cells that secrete CXCL12, a
chemokine that promotes HSC maintenance.
Stem cells reside in specialized microenvironments
created by supporting cells that promote stem cell
maintenance through the production of factors that
regulate self-renewal and differentiation. Although the
identification of such niches offers the opportunity for
discovering key factors that regulate stem cell function,
these niches are just beginning to be localized and char-
acterized in mammalian tissues. For example, it has
been possible to highly purify mouse hematopoietic
stem cells (HSCs) for nearly 20 years, but only in recent
years have researchers begun to characterize the
niches in which HSCs reside.
Most work on HSC niches has focused on the endos-
teum, the inner surface of the bone that interfaces with
the bone marrow (Figure 1). The endosteum is covered
with osteoblasts (bone-generating cells) and osteo-
clasts (bone-degrading cells), which are thought to
secrete or activate a variety of factors that regulate
HSC function. Genetic manipulations that increase
osteoblast numbers in mice also increase the number
of HSCs in bone marrow (Calvi et al., 2003; Zhang
et al., 2003). Various factors, such as angiopoietin, that
appear to regulate the maintenance or the numbers of
HSCs in the bone marrow are expressed by osteoblasts
(Arai et al., 2004). Osteoclast activity (Kollet et al., 2006)
and the high amounts of calcium generated by bone
resorption (Adams et al., 2006) have also been impli-
cated in promoting HSC maintenance and localization
near the endosteum. There are also imaging data that
suggest that some HSCs reside at or near the endos-
teum (Nilsson et al., 2001; Zhang et al., 2003; Arai et al.,
2004; Kiel et al., 2005).
The endosteum, however, cannot be the whole story.
When osteoblasts are ablated from the bone marrow,
HSC frequency actually increases over time, whereas
differentiating cells disappear from the bone marrow
(Visnjic et al., 2004). This observation suggests that
HSCs may be less acutely dependent upon osteoblastsfor their maintenance than differentiating cells. More-
over, other cells must be capable of creating HSC niches
because HSCs can be maintained for long periods of
time in extramedullary tissues like the spleen and liver,
tissues which do not contain endosteum or bone.
Until recently, attempts to directly localize HSCs within
the bone marrow depended either on markers whose
specificity was uncertain or on markers that were known
to yield low levels of purity (and therefore high levels of
uncertainty). As a result, it had not been possible to
precisely and systematically examine the localization of
untransplanted HSCs in situ. The fundamental problem
was that although it has long been possible to highly
purify HSCs by flow-cytometry, this involved combina-
tions of antibodies that are too complex for localizing
rare cells in tissue sections. This problem changed with
the discovery that HSCs can be highly purified with a sim-
ple two-color combination of SLAM family receptors:
45% of single CD150+CD482CD412 bone-marrow cells
(CD48 and CD41 are imaged with the same fluoro-
chrome) give long-term multilineage reconstitution upon
transplantation into irradiated mice (Kiel et al., 2005). The
localization of HSCs in hematopoietic tissues with these
markers revealed that about two-thirds of HSCs in the
bone marrow and in the spleen are adjacent to sinusoids
(Kiel et al., 2005). Sinusoids are specialized vessels that
allow cells in venous circulation to extravasate into he-
matopoietic tissues (Figure 1). Some bone-marrow
HSCs also localize to the endosteum or to other places.
The role of the endosteum in the regulation of HSC
function coupled with the localization of most HSCs to
sinusoids raised several questions. Do sinusoids create
vascular niches that regulate HSC maintenance, or are
the HSCs in these locations just on their way to the
endosteum (Figure 1)? In the bone marrow, are there
multiple niches that regulate distinct subsets of HSCs
in different ways, or are there common elements that
allow HSCs to be maintained by similar mechanisms
in both vascular and endosteal locations?
In this issue of Immunity, Sugiyama et al. provide
a mechanism for the maintenance of HSCs in vascular
niches as well as a functional link between the vascular
and endosteal niches (Sugiyama et al., 2006). They dem-
onstrate that sinusoids are surrounded by reticular cells
that secrete unusually high amounts of CXCL12 (also
known as stromal-cell-derived factor (SDF)-1), a chemo-
kine that is required for HSC maintenance. HSCs that
localized around sinusoids were usually in contact with
these reticular cells. Moreover, Sugiyama et al. also
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863Figure 1. HSCs Are Maintained Adjacent to
CXCL12-Expressing Reticular Cells in Vascu-
lar Niches as Well as in Other Locations, Such
as at the Endosteum
Most HSCs reside adjacent to sinusoids in
vascular niches marked by the presence of
perivascular reticular cells that express
unusually large amounts of CXCL12, a
chemokine that regulates the migration and
maintenance of HSCs in the bone marrow.
Some HSCs also reside at the endosteum or
in other locations, where they are also usually
present adjacent to CXCL12-expressing
reticular cells.demonstrated that the HSCs that localized to the
endosteum or to other locations were also usually adja-
cent to CXCL12-secreting reticular cells. The consistent
presence of HSCs adjacent to CXCL12-secreting reticu-
lar cells, irrespective of whether the HSCs were in vascu-
lar or endosteal locations, provides a functional link
between vascular and endosteal niches and raises the
possibility that these niches may not be so different
after all.
The main receptor for CXCL12 is CXCR4, which is
expressed by HSCs (Peled et al., 1999). CXCL12-CXCR4
signaling is required for the colonization of bone marrow
by HSCs during development (see references cited in
Sugiyama et al. [2006]) and regulates the engraftment
of HSCs after transplantation (Peled et al., 1999).
CXCL12 has previously been implicated in the regula-
tion of HSCs in both vascular and endosteal (Kollet
et al., 2006) niches; however, in this study, Sugiyama
et al. knocked green fluorescent protein into the Cxcl12
locus to determine which cells in the bone marrow
express the most CXCL12. They found that perivascular
reticular cells expressed much more CXCL12 than en-
dothelial cells, osteoblasts, or other cells, suggesting
that these reticular cells are the principal source of
CXCL12 that regulates bone-marrow HSC maintenance.
Sugiyama et al. confirmed that CXCL12-CXCR4 sig-
naling is required autonomously for the maintenanceof HSCs in the bone marrow by conditionally deleting
a floxed allele of Cxcr4 from adult HSCs, with Mx-1-
Cre activated by poly(I)-poly(C) administration. Condi-
tional deletion of Cxcr4 in hematopoietic cells led to
a pronounced reduction in the frequency of CD342
c-kit+Sca-1+Lineage2 HSCs in the bone marrow and in
HSC activity after transplantation into irradiated mice.
To directly test whether the effects of Cxcr4-deficiency
on HSCs were cell-autonomous, the authors trans-
planted Mx-1-Cre+Cxcr4fl/2 bone-marrow cells into irra-
diated, wild-type recipients. After the donor cells had
stably engrafted, the recipient mice were treated with
poly(I)-poly(C) so that Cxcr4 from the donor cells can
be deleted. This manipulation led to the loss of donor
HSCs over time. This observation makes it unlikely that
the loss of HSCs was indirectly caused by the loss
of other CXCR4-expressing cell in the bone marrow
because the bone marrow in these mice contained
a mixture of Cxcr4-deficient and wild-type cells.
Finally, the authors examined the localization of HSCs
in tissue sections. By using mice in which green fluores-
cent protein was knocked into the Cxcl12 locus, the au-
thors identified reticular cells that expressed unusually
high amounts of CXCL12 throughout the medullary
bone marrow (Figure 1). These cells were frequently
associated with sinusoids, although occasionally they
were found in other locations such as the endosteum.
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of HSCs (identified in sections as CD150+CD482CD412
cells in some experiments) were closely associated with
these CXCL12-expressing reticular cells. Although most
of the HSCs were located around sinusoids, as ob-
served previously (Kiel et al., 2005), even the HSCs that
were localized to the endosteum or in other locations
were frequently adjacent to CXCL12-expressing reticu-
lar cells. Coupled with the observation that CXCR4-
CXCL12 signaling is required for HSC maintenance in
the bone marrow, these results strongly suggest that
CXCL12-expressing reticular cells contribute to the
formation of vascular niches that maintain many bone-
marrow HSCs. Because the CXCL12-expressing reticu-
lar cells were also adjacent to HSCs at the endosteum,
these results also suggest that the vascular and endos-
teal niches may employ some common mechanisms for
maintaining HSCs.
Although recent reviews of the literature on HSC
niches have focused almost exclusively on the function
of osteoblasts, the study by Sugiyama et al. suggests
that other cells also play critical roles and that factors
that regulate HSC maintenance are not necessarily
produced primarily by osteoblasts. Ultimately, so that
the physiological origins of factors that regulate HSCs
can be elucidated, it will be necessary to conditionally
delete these factors from specific cell types in the bone
marrow. Only then will it be possible to elucidate the
relative contributions of different cell types to the main-
tenance of HSCs. It is likely that many cells contribute
to HSC maintenance, potentially including endothelial
cells, mesenchymal progenitors, megakaryocytes, plate-
lets, and adipocytes, in addition to CXCL12-expressing
reticular cells (Sugiyama et al., 2006), osteoblasts (Calvi
et al., 2003; Zhang et al., 2003), and osteoclasts (Kollet
et al., 2006). Some contributions to the niche may be di-
rect, whereas other contributions may act indirectly
through third-party cells. Some factors may beImmunity 25, December 2006 ª2006 Elsevier Inc. DOI 10.1016/j.immuni.2006
Anergic B Cells Caught in the Act
Tolerance of B-lymphocytes to autoantigens is estab-
lished by clonal deletion, receptor editing, and anergy.
In this issue of Immunity, Merrell et al. (2006) have now
identified that T3 ‘‘transitional’’ B cells in the spleen
are not developmental intermediates but rather amajor
population of anergic B cells.
The rearrangement of V, D, and J segments of the IgH
and IgL chain loci and the insertion of P and N nucleo-
tides at the joints during B cell development generate
a seemingly endless variety of diverse B cell receptors
(Melchers et al., 2000). It is likely that newly generateddelivered by cell-cell interaction, whereas others may
be diffusible and act at a distance. HSCs niches are
likely to be complex assemblies of multiple cell types
that occur around sinusoids, at the endosteum, and in
other locations.
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repertoires of BCRs on immature B cells display a ran-
dom spectrum of affinities to any given antigen, includ-
ing autoantigens presented to them in the bone marrow.
Most of the newly generated B cells will have either no
or low affinities to a single given autoantigen, and the
frequencies of antigen-binding B cells are expected to
decrease with increasing affinities. In contrast, any
given BCR-expressing immature B cell is expected to
have a similar spectrum of avidities to different anti-
genic structures, including the autoantigens presented
to it in the bone marrow. This variety of autoantigens
should comprise all those antigens expressed on and
in live and dying bone marrow cells, including intercellu-
lar cytoplasmic and nuclear structures. Cell death is
rampant in bone marrow resulting from nonproductively
rearranged or negatively selected B lineage cells. Given
